Cours RXi Pharmaceuticals Corp Nasdaq
Actions
US74979C5013
Recherche biotechnologique et médicale
CA 2024 * | - | CA 2025 * | 75 M 68,21 M | Capitalisation | 3,61 M 3,29 M |
---|---|---|---|---|---|
Résultat net 2024 * | -9 M -8,19 M | Résultat net 2025 * | 47 M 42,75 M | VE / CA 2024 * | - |
Trésorerie nette 2024 * | - 0 | Trésorerie nette 2025 * | - 0 | VE / CA 2025 * | 0,05 x |
PER 2024 * |
-0,43
x | PER 2025 * |
0,21
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 99,41% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/09/17 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Director/Board Member | 73 | 02/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/04/13 |
Varia. 1 janv. | Capi. | |
---|---|---|
+42,17% | 50,93 Md | |
-0,46% | 42,12 Md | |
+49,62% | 42,05 Md | |
-7,20% | 29,18 Md | |
+13,56% | 26,02 Md | |
-22,11% | 18,9 Md | |
+7,71% | 13,21 Md | |
+24,16% | 12,17 Md | |
+30,19% | 12,16 Md |